**Respiratory Distress Syndrome** or Hyaline Membrane Disease M.C.C of Respiratory failure disease A in the 2<sup>sr</sup> 2 days HMD (2 types) " Surfactant Production Lo function + Conc. Full term o 5% of nn. at Risk V GBS E Can't d'lleventiate 😣 CX: eX: 2 Dabys 2 babys full term - 34 w. 35 w. 370 Prognosis) is both RDS both RDS due to S'n >2 due to leading Couse for Prematurity ( infant 4 DM Molher Will wei sing ( Most Severe) - hyPoxia Mythiple Causes and to high frequence counselation + Nitric oxide Respiratory distresses surfactant Concentration 2 Lo as Respiratory inf. Good More is Su function I alca si م من موجودين بالاردن insuline of function of surfactant leading Cause & [Vicious circle - Jul 1 de CHi inhibit Severe death D leading cause for PPHL > Poly Cythemia Meconium aspiration -> pnoumothorax gir leak  $\bigcirc$ > Multiple HF ~ CHD RDS Not always from Promature # \* single Most important factor for RDS - promaturity the deficiency is a Relative

in Compatible w/ life & absolute it list Viability age -> 24 w. 3 bad according to situation of MICU. to (intervention of MICU. to (intervention) Rick for L \* (interior 12 man ) Risk for bronch-Pulmonary dysplasia (BPD) 100% Not the ROP of States Spashic certaral cp = < 5009/ 40%. IVH / Incidence GA no. diseases JI US & incidine Ju cive & now offer the birth with Prognosis Ħ \* extremely Premalure Baby ~ (128) 50% Very Plemature - 28-32 30%. Premature - >32 GROP Risk Accrease Incidence JU Neoterm -> 36 Gull-term \_\_\_\_ 37 5%. due to vaccume frisk & RDS ~ very very high \* extremely low Birth wt. \_> < 500 g X1% PBD 100%. Very Plemature -> 500-1000 54% Premature - 1000-1250 36%. decrease Incidence JU Gull-term \_\_\_\_ 1250-1500 221. \* improvement in we >1 kg - 22% \* factors prevent RDS -> stevoid for high Risk mom

Reording \* RDS affect all Paces [ to in Developed] & Most in Caucasian 🛪 Contributing factors 🗶 Neonates younger than 37 weeks Weight less than 2500g Maternal diabetes Cesarean delivery without preceding labour elective Fetal asphyxia but emergency • Second part of twins protective - Transient tachypnea of the newborn (TTN) another cause for PPHI ttt : into bation White infants asphyxiq full term baby, but Problem in function & = - hypoxic ischemic encephalopath توانع ن Normal function \_ PH the disease of full term baby \* PPHI - & hyperia - Resp. acidosis -> PH+ -> pulmonary RE-PLE shunt \_p further hypoxia Vaso-Constriction Port (ant. Contanell asis \_ + (foramen ovale "") Co1. / Lactic systemil vasodilatation Acidosis Trigger Chemoreceptors + · More hacky cardia Move shurt & Complications of Prematurity :- 0 only treatment :- ( Vicious Circle 35% PDA + surfactant therapy Delective vasodilation (Nitric oxide) one I the Causer NOT complete Pulmonary Hge Lop systemic hy Polension # high Geogramicy RR in nn. ossilation 600-3000 Secondary surfactant deficiency may occur in \* Conventional ventilation ~ 80 infants with the following: 3) como Machine **∼** Pulmonary infections e.g. GBS **V** Pulmonary hemorrhage -vaffect the ∼ Meconium aspiration pneumonia 🧹 function of Surfactant  $\sim$  Oxygen toxicity; barotrauma or volutrauma to the lungs V Congenital diaphragmatic hernia -> scaphoid abdomen DEEC : intubation sever cyanosis


## surfactant 8-

I Surfactant lettion at the end of expiration (framplete atelactesis). 1) large vent-elation / perfusion mismatch 2 respiratory acidosis + atelactesis. 3 Dead space M -> can't maintain Functional residual capacity @ 1 complience 5 massive hypoxia. La metabolic acidosis -> hypoxia. Positive earl expiratory pressure [peep] nydrophelic [Head] [Jai] u type of ß \* Protein in hydro Phopic surfactant

معلاما کانتے الغترة ابكر ركون امن 🕹 الغترة المركز ركون امن
Factors decrease the risk of RDS: 24-54w. (2 w.) ## Phospholipids Proteins
Use of antenatal steroids for any PRisk Mom
Pregnancy-induced or chronic maternal (hypertension) -> hypexia Pregnancy (stress) Prolonged rupture of membranes -> P Risk + sePsis # Psurjer steried P induced steried surge
Maternal narcotic addiction (hronic ROM ~ oligohydraminous (106R) (PreeclamPria)
Risk f RDS # Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de danning en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates syndrems (BDS), Escept Stal de dates en at increased als de reprinting dates en at increa
* Oxygenation; oxygen
Pathophysiology: * ventilation : oxygen + pressure
Lung surfactant deficiency is the primary cause
<ul> <li>Pulmonary surfactant synthesis, in type II pneumocytes</li> <li>surfactant production begins at 24-28 weeks of gestation, and gradually increases</li> </ul>
until full gestation
• The cause of respiratory distress syndrome is relative deficiency of surfactant,
2 <sup>4</sup> line which <u>decreases</u> :
- titt:- lung compliance I + , fliable Chest L intra-thuracic negative Pressure PEEP functional residual JFRC (Premature baby) sub room ( - Sub ro
increased dead space.
No exchange (air blanchogram)
→ large ventilation-pertusion (V/Q) mismatch right-to-lett shunt. $\mathcal{M}_{Ask}$
C-PAP ( cont. (+) Airway Pressure ) # # to Provent (9+elactosic) (BPD)
Ailfuse
* surfactant _ provent collapse at end of expiration ###
t evol exp. Pressure.
-> dilluse atelaclasis -> PVIQ Mis match -> Pproz -> pytmonary -> opened -> pt-16 should
b Por vaso-const.
Mixed acidemia w/ hypoxia (Melabolic) ~ a crumulation hypoxic in rissue
hypoxia Prematurity
respiratory - Inadequate Structurally Inadure Lung
Acidosis Acute V/C Mismatch Chronic Process Hypercarbia
RDS VS TTU Neonatal Respiratory Distress USMLE Step 2 CK Pediatrics Respiratory distress USMLE Step 2 CK Pediatrics Respiratory distress Transient tachypnea of
syndrome newborn Pulmonary Unflammatory Vasoconstriction Cell Influx Antioxidant
CAE POINT OF MPT // Provide Stationg     Endothelial & Epithelial cell Injury       Wr. Kopy     Repertusion
(ung recruitment) HAS Roby miliatr Production Prod
Department         Physical Exam Findings: Tachypnea & 1 Sp0; in vital signs         HMD or RDS         BPD



- Progressive atelectasis damages endothelial and epithelial cells lining distal airways, resulting in :
- > exudation of fibrinous matrix derived from blood.
- Hyaline membranes that line the alveoli may form within a half hour after birth.




## ✓ Chemical mixture that decreases surface tension ✓ Lines the air-fluid interface in alveoli

- $\sim$  Prevents at electasis at the end of expiration
- Synthesized in alveolar type II cells and stored in lamellar bodies

Pulmonary Surfactant	SP-B SRequired for normal ruthmanary function Mutation result in deficiency SP-B Can cause severe lung disease that is lethal in perinatal
Function of lung surfactant	period
decreases surface tension during expiration Sutfactant film	SP-C Promotes formation of phospholipid film lining of alveoli
allows the alveolus to water and a second se	<ul> <li>✓ Human with SP-C deficiency develop interstitial pulmonary fibrosis in early childhood</li> <li>→ SP-C deficiency do not cause respiratory distress at birth</li> </ul>
maintains functional	→ SP_A and SP_D They are host defense of the lung (
Pulmonary surfactant deficiency	<ul> <li>→ They have carbohydrate recognition domain allows coating, and phagocytosis of virus and bacteria</li> </ul>
> Atelectasis causes lung inflammation and	
<ul> <li>respiratory epithelial cell injury</li> <li>Decrease fluid absorption and lung edema</li> <li>Accumulation of neutrophils in the lung</li> </ul>	
Surlaclash Phospholifiq - o lecithine & sphingcomycline	functionally phospholipid
approteins q J lipoprotein keep incoming in August	
ao? -> Upid > Ledition.	
hydrophilic Rafio JI & vare	
-: CVSI 2? # Lung ) >is 60 pero	
	1 locald
aspiration vote Vot all >2 Mature	denory
Deconium & function aspilation votine Not all 2 Pulmonary Hge. The time 2 Matule V 1-3 immalance 52	. delay delivery

- Inid - 24 . Timing of lung surfactant : amniohic The timing of lung surfactant or (Lecithin) production : Good Gnl. on Alvert: 036 -🗸 At 32-34 weeks fetal cortisol increase 🛛 —>> Stimulate Type II pneumocyte cells J By 34-36 weeks sufficient amount of Lecithin secreted into alveolar lumen & Excreted into the amniotic fluids 🖊 Lecithin concentration in amniotic fluid indicate lung maturity 🛛 🗍 > does not correlate w/ severity # 00 - improving / we don't need X-ray to Confirm diagnosis. or for surfactant 02 to be improved -s need low Conc. 4 Been: Just Ugsal Cannula or C-PAP Rarelly -> Mechanical Ventilation # Prominent perihilar streaking Fluid in the fissures
 Small pleural effusions may be seen 30~ als as + surfactant therapy Room + intubation < Patchy infiltrates have also been described ? (Risky therapy) NICU ( LICE Cois IC / U)U GBS (ron't differentiate by X-Ry lung derucruitment (1) Bacteria ( Pneumonia) (3-5 d.) anti-biotics فصع > lung high Pressure # Collapsed high volume 3 Anemia high or (4) hy Pogly (emig BPD 5) Meronium 95P. ) hypothermia Dulmonary air leak (Pneumothorax) \* Diaphragmatic hernia 32 - 3 w A (9) Caroliac anomaly (yanosis Alter delivon diagnosis ) indication for and as -! 5,2-4 ICU & ater love, Transposition w/o VSD auscultation. C-PAP area Trinuspid glivesia w/ VINY Small VSD & ASD 3) total anomalus Ruturn the obsc. type Putable (-PAP > DX ? / hyperbanic Oz (1) > Prostanglandine Er il dectra depredant Innsion \* Spure Cranosis diaphragmatic Scaphoi d abolomen intubation untill proven other wise hoinia (decomplession) NG tube + Not by X 2st line of Mx - 002 # UNU Service the annuar





Need Supportive 666 # Oxygenation reatment ENS - Swfactant (Ventilation) 10/3 infection Control \* Plematurity -> Most important RF -D Groals: - S.E choë is the I RDS &V » SPOL -> 88-92% Oxygenation !-\* 02-0 50-50 oxygen Radicals ->>> BPD × P(or)-8 35-45 over ventilation \_\_\_ ROP 1 P(02 ans 's accepted and Us' <35 Apreg J if low 12602 55 PVL \_ Chorio amnionifis Vasal cannula \*" failure ESCX hubation R hypocarbia HIE hybrarbia la Risk for Aprea C-PAP Sortactant & Not improve -B Mechanical Vent. (PAD failure. Next Step 12 fill - 8 21 - 60% or 80% # # sulfactant + intrubation deep -> 5-7 \* < 30 week -- intrubation + surfactort [by endotrached tube) V [don't wait for x-ray] **Respiratory Treatment of RDS** 1)Less than 30 weeks If more than 30 weeks 2) 6 Nasal CPAP apnea need tectile stimulation Using CPAP soon after delivery *reduces the number* 3) 1 apnea need ambu bag of babies requires ventilation Indication of CPAP 4) congenital In delivery room for babies at risk of RDS diaphragmatic hernia Babies on low flow oxygen with respiratory distress 5) muconeum aspiration Mechanical ventilation ? On blood gases 6) PaO2 less What is your O<sub>2</sub> targets ? o SpO<sub>2</sub>: 88-92% than 55 o P<sub>co2</sub>: 45-55 mmHg o Maintain PaO<sub>2</sub> at 50-80 mmHg 7)PaCo2 more than 55 O PH . 8) failure of CPAP

 $\rightarrow 10_2 / \downarrow CO_2$ No Hypervent → PVL, Rol, BPD) -> What is your target? Paoz 50-20 If PaO2 > 100 for 24 hrs -> Hypervent -> How Can 1 maintain that ? حص موجدد · Continous monit of ABG ... there is a Device عندنا · Jeg 15, -> By 02 Sat (Pa02 = 02 Sat - 30) 28-30 = 58 Aco2 4> 28-92 92-30 = 62 PaO2 -> Normal PCO2 in neonate = 45.55 in first I days it after 7 days neonate on Vent, accept PCO2 up to 70. "Permisive Hypercarpia" -> How to maintain Or Sal: at the level i want 2. . <30 week -> Intubation and surfactant. (Mech Vent) لى تحلق منه من اقون فرصة ( يه ادل ما يحسن المربع) Is Baby w/ stiff lang need certain amount of pressure Provided by Mach vent. La But the pressure required is decreased after giving surfactant So we need to Lower the pressure provided by the Ventilator as soon as possible. Is if we don't lower the pressure (from Vent) after giving surfactant, Prennothorous will be the result Eg. 30 week-old boby w/ RDS, you start mech Vent and gave him Surfactant, After 2 hrs the bolog is status is detorierating with Hypotension; Cyanosis and retractions .... 1> The baby has previnathorax ( due to high pressure) X Vay 11 minu le siell Transilkunination de Ntinner > Tilal Volcime = 7-14 /Kg · >30 weeks -> Nasal Canula or CPAP Nh in neonate •PEEP: ~2. •PEEP: 5-10 4 6-3 Ho So use It if o FiOz: Up to 100% Mild case · Continous pressure (Aprea) > firstly give Califeire Citate, If no response, Put the Baby on CPAP. L Agitation/Stimulation if the baby ->30 week I- Nasal Canula جير ايش الك ما معطيم 2. CPAP 3 - Intubation and Surfactant Surfactant SSS - هذا حا متحرف بالسلام أن القادفة

	-: sur factart SI ziji *
<ul> <li>Natural lung surfactant</li> <li>Alveofact - extracted from cow lur</li> <li>Curosurf - extracted from materia</li> <li>Infasurf - extracted from calf lung</li> </ul>	I derived from minced pig lung
	cow lung with additional DPPC, palmitic
<ul> <li>Curosurf (Poractant alfa) Dosage: Intratracheal: Initial: 2.5 may repeat 1.25 mL/kg/dose (100m for up to 2 additional doses; maximum total dose: 5 mL/kg</li> </ul>	
Precautions: Correction of acidosis, hypotensic hypothermia is recommended price	Or to administration.       Warnings!!         Curosurf: if transient episodes of bradycardia and decreased oxygen saturation occur         Discontinue the dosing procedure and initiate         measures to alleviate the condition         Curosurf: produces rapid improvements in lung oxygenation and compliance that may require
PBHL	+ intribution allow while reductions in vertiletor settings and Fio2 + intribution allow while all of a fions & auma Vocal Good 2 Complications & achea Perforation 6 bleeding
Side effects of Animal-Derived Surfactant         ★ Fuctuation of the → cause hemotives         • Transient hypoxia         • Transient hypoxia         • A Conte airway obstruction         • A Conte airway obstruction         • Transient full in blood pressure and cerebral blood flow         • Slight increase in risk of pulmonary hemorrhage         • No long-term effect on babies         • Power preumothorces with slightly reduced mortality (?) rate compared to infant treated with synthetic surfactant         • Potential sensitization to animal proteins	BPD <u>Mechanical</u> Ventilation Pneumothorax Pneumomediastinal subsurgical emptysema

## Supportive Ett:-





- + + + e

Rish factors for NEC:-

-> Prematurity, PDA, ischemia, infection CIP :- PERFORMINAL DICTEMENT NICE CONST PERFORMINAL DICTEMENT NICE CONST PERFORMINAL DICTEMENT PERFORMINAL abd. distention, bleeding (rectum), X-Ray bowel -+

MX:- - Medical: triple antibiotic Correction acid-base surgical balance 2 Mechanical Ventilation if there is IV Eluids Biliary duct Perforation V failure of Medical Kespiratory support

